JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Затворен

СекторЗдравеопазване

3.37 2.43

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.24

Максимум

3.38

Ключови измерители
By Trading Economics
Приходи	4.1M -5.7M
Служители	34
EBITDA	3.1M -6.8M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+498.8% upside

Дивиденти
By Dow Jones
Следващи печалби	12.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-50M 338M
Предишно отваряне	0.94
Предишно затваряне	3.37

Настроения в новините

By Acuity

50%

157 / 348 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.04.2026 г., 23:15 ч. UTC

Значими събития в новините

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27.04.2026 г., 23:08 ч. UTC

Печалби

Значими двигатели на пазара

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27.04.2026 г., 23:58 ч. UTC

Печалби

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27.04.2026 г., 23:58 ч. UTC

Печалби

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27.04.2026 г., 23:56 ч. UTC

Печалби

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27.04.2026 г., 23:56 ч. UTC

Печалби

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27.04.2026 г., 23:48 ч. UTC

Пазарно говорене

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27.04.2026 г., 23:42 ч. UTC

Пазарно говорене

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27.04.2026 г., 23:34 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27.04.2026 г., 23:30 ч. UTC

Пазарно говорене

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27.04.2026 г., 23:08 ч. UTC

Пазарно говорене

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27.04.2026 г., 23:02 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

27.04.2026 г., 23:02 ч. UTC

Пазарно говорене

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27.04.2026 г., 22:42 ч. UTC

Пазарно говорене

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27.04.2026 г., 22:10 ч. UTC

Печалби

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27.04.2026 г., 22:09 ч. UTC

Печалби

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27.04.2026 г., 21:56 ч. UTC

Печалби

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27.04.2026 г., 21:55 ч. UTC

Печалби

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27.04.2026 г., 21:55 ч. UTC

Печалби

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27.04.2026 г., 21:44 ч. UTC

Печалби

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27.04.2026 г., 21:43 ч. UTC

Печалби

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27.04.2026 г., 21:41 ч. UTC

Печалби

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27.04.2026 г., 21:41 ч. UTC

Печалби

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Basic Materials Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Financial Services Roundup: Market Talk

27.04.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

27.04.2026 г., 20:39 ч. UTC

Печалби

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

498.8% нагоре

12-месечна прогноза

Среден 20 USD 498.8%

Висок 20 USD

Нисък 20 USD

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

157 / 348 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.